AnHorn Medicines Co., Ltd.

AnHorn Medicines, founded in 2020 in Taipei, Taiwan, is a novel drug discovery company focused on Targeted Protein Degradation (TPD) using its BIGPRO® platform. Its proprietary AI platform AIMCADD® designs and screens drug candidates for cancer, neurodegeneration, and aging diseases. AH-001, a first-in-class protein degrader for androgenetic alopecia, entered Phase I clinical trials in the US in March 2025.